Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Gilead Presents New HIV Treatment And Cure Research Data
Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...
Business Wire4d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
“Gilead is fueling the next wave of innovation ... vital importance of catalyzing research reaching towards a cure.” Biktarvy Demonstrates High Rates of Viral Suppression in People with ...
Nasdaq4d
Gilead Presents Encouraging Long-term Data For Biktarvy In People With HIV And HBV Coinfection
(RTTNews) - Gilead Sciences, Inc. (GILD) Wednesday said it presented encouraging long-term data from ALLIANCE study. ALLIANCE is an ongoing Phase 3 study to evaluate Biktarvy versus dolutegravir ...
Merck releases positive phase 3 data on daily oral HIV drug
In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...
Benzinga.com4d
Gilead Presents New HIV Treatment And Cure Research Data
Biktarvy maintained HIV-1 suppression in 95. ... with zero discontinuations due to TEAEs. Also Read: Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention At CROI 2025, the primary ...
Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Applied Clinical Trials Online2d
Doravirine/Islatravir Regimen Shows Promise in Multiple Phase III Trials for the Treatment of HIV
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
Investing4d
Gilead reports high efficacy in HIV and HBV treatment study
Gilead Sciences, Inc. (NASDAQ ... The data included results from a Phase 3 study on Biktarvy’s efficacy in treating HIV and HBV co-infection, a Phase 2 study on a long-acting treatment regimen ...
Nasdaq3d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Biktarvy Demonstrates High Rates of Viral Suppression in People with HIV/HBV Coinfection ALLIANCE (NCT03547908) is an ongoing Phase 3 study evaluating Biktarvy versus dolutegravir 50 mg (DTG ...
The Financial Express2d
Gilead Sciences: A rare Nasdaq gem with consistent returns across time horizons
To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.